Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease

References

• Holden, N. J., J. M. Williams, M. D. Morgan, et al. 2011. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann. Rheum. Dis. 70: 2229–2233
   PubMed Web of Science ®Google Scholar
• Luu, V. P., M. I. Vazquez, and A. Zlotnik. 2014. B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47: 1–12
   PubMed Web of Science ®Google Scholar
• Krumbholz, M., U. Specks, M. Wick, et al. 2005. BAFF is elevated in serum of patients with Wegener’s granulomatosis. J. Autoimmun. 25: 298–302
   PubMed Web of Science ®Google Scholar
• Thien, M., T. G. Phan, S. Gardam, et al. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785–798
   PubMed Web of Science ®Google Scholar
• Smith, R. M., R. B. Jones, M.-J. Guerry, et al. 2012. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64: 3760–3769
   PubMed Web of Science ®Google Scholar
• Smith, K. G. C., R. B. Jones, S. M. Burns, and D. R. W. Jayne. 2006. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54: 2970–2982
   PubMed Web of Science ®Google Scholar
• Jones, R. B., A. J. Ferraro, A. N. Chaudhry, et al. 2009. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60: 2156–2168
   PubMed Web of Science ®Google Scholar
• Specks, U., P. A. Merkel, P. Seo, et al. 2013. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369: 417–427
   PubMed Web of Science ®Google Scholar
• Rhee, E. P., K. A. Laliberte, and J. L. Niles. 2010. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol. 5: 1394–1400
   PubMed Web of Science ®Google Scholar
• Roubaud-Baudron, C., C. Pagnoux, N. Méaux-Ruault, et al. 2012. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J. Rheumatol. 39: 125–130
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba, R., J. M. Golbin, K. A. Keogh, et al. 2012. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 64: 3770–3778
   PubMed Web of Science ®Google Scholar
• Stasi, R. R., E. E. Stipa, G. G. Del Poeta, et al. 2006. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45: 1432–1436
   PubMed Web of Science ®Google Scholar
• Miloslavsky, E., U. Specks, P. Merkel, et al. 2013. Clinical outcomes of remission induction therapy for severe ANCA-Associated vasculitis. Arthritis Rheum. 65: 2441–2449
   Google Scholar
• Guillevin, L., C. Pagnoux, A. Karras, et al. 2012. Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. ACR Annu. Meeting Abstr. 64: 1652
   Google Scholar
• Popa, C., M. J. Leandro, G. Cambridge, and J. C. W. Edwards. 2007. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46: 626–630
   PubMed Web of Science ®Google Scholar
• Roll, P., A. Palanichamy, C. Kneitz, et al. 2006. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54: 2377–2386
   PubMed Web of Science ®Google Scholar
• Roll, P., T. Dorner, and H.-P. Tony. 2008. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58: 1566–1575
   PubMed Web of Science ®Google Scholar
• Thiel, J., U. Salzer, F. Hässler, et al. 2013. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity. 46: 429–438
   PubMed Web of Science ®Google Scholar
• Venhoff, N., N. M. Effelsberg, U. Salzer, et al. 2012. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE. 7: e37626
   PubMed Web of Science ®Google Scholar
• Pullerits, R., M. Ljevak, J. Vikgren, and M. Bokarewa. 2012. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand. J. Immunol. 76: 411–420
   PubMed Web of Science ®Google Scholar
• Jennette, J. C., R. J. Falk, K. Andrassy, et al. 1994. Nomenclature of systemic vasculitides – proposal of an International Consensus Conference. Arthritis Rheum. 37: 187–192
   PubMed Web of Science ®Google Scholar
• Leavitt, R. Y., A. S. Fauci, D. A. Bloch, et al. 1990. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 33: 1101–1107
   PubMed Web of Science ®Google Scholar
• Mukhtyar, C., L. Guillevin, M. C. Cid, et al. 2009. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68: 310–317
   PubMed Web of Science ®Google Scholar
• Hellmich, B. B., O. O. Flossmann, W. L. W. Gross, et al. 2007. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66: 605–617
   PubMed Web of Science ®Google Scholar
• Kreuzaler, M., M. Rauch, U. Salzer, et al. 2012. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J. Immunol. 188: 497–503
   PubMed Web of Science ®Google Scholar
• Stone, J. H., P. A. Merkel, R. Spiera, et al. 2010. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363: 221–232
   PubMed Web of Science ®Google Scholar
• Jones, R. B., J. W. C. Tervaert, T. Hauser, et al. 2010. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363: 211–220
   PubMed Web of Science ®Google Scholar
• Turk, J. L., and D. Parker. 1982. Effect of cyclophosphamide on immunological control mechanisms. Immunol. Rev. 65: 99–113
   PubMed Web of Science ®Google Scholar
• Lavie, F., C. Miceli-Richard, M. Ittah, et al. 2007. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66: 700–703
   PubMed Web of Science ®Google Scholar
• Pers, J. -O., V. Devauchelle, C. Daridon, et al. 2007. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 56: 1464–1477
   PubMed Web of Science ®Google Scholar
• Hiemstra, T. F., M. Walsh, A. Mahr, et al. 2010. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 304: 2381–2388
   PubMed Web of Science ®Google Scholar
• Azar, L., J. Springer, M. Xu, et al. 2012. Long-term outcome of patients with granulomatosis with polyangiitis (Wegener’s) treated with rituximab. ACR Annu. Meeting Abstr. 64: 1544
   Google Scholar
• Pagnoux, C., A. Mahr, M. A. Hamidou, et al. 2008. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359: 2790–2803
   PubMed Web of Science ®Google Scholar
• Smith, R. M., R. B. Jones, and D. R. Jayne. 2012. Progress in treatment of ANCA-associated vasculitis. Arthritis Res. Ther. 14: 210–221
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba, R., F. C. Fervenza, and U. Specks. 2012. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr. Opin. Rheumatol. 24: 15–23
   PubMed Web of Science ®Google Scholar
• Tamura, N., R. Matsudaira, M. Hirashima, et al. 2006. Two cases of refractory Wegener’s granulomatosis successfully treated with rituximab. Intern. Med. 46: 409–414
   Web of Science ®Google Scholar
• Eriksson, P. P. 2005. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern. Med. 257: 540–548
   PubMed Web of Science ®Google Scholar
• Keogh, K. A. K., S. R. S. Ytterberg, F. C. F. Fervenza, et al. 2006. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173: 180–187
   PubMed Web of Science ®Google Scholar
• Wendt, M., I. Gunnarsson, J. Bratt, and A. Bruchfeld. 2012. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand. J. Rheumatol. 41: 116–119
   PubMed Web of Science ®Google Scholar
• Omdal, R., K. Wildhagen, T. Hansen, et al. 2005. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand. J. Rheumatol. 34: 229–232
   PubMed Web of Science ®Google Scholar
• Stone, J. H., P. A. Merkel, P. Seo, et al. 2011. Extended follow-up of treatment with rituximab versus cyclophosphamide for remission-induction of ANCA-associated vasculitis: which subsets are at greatest risk for flare? ACR Annu. Meeting Abstr. 63: 2432
   Google Scholar
• Palanichamy, A., P. Roll, R. Theiss, et al. 2008. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis Rheum. 58: 3665–3674
   PubMedGoogle Scholar
• Leandro, M. J., G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards. 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54: 613–620
   PubMed Web of Science ®Google Scholar